Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaxanib + interferon alfa-2b
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Semaxanib + interferon alfa-2b is a combination therapy investigated for the treatment of advanced kidney cancer. Semaxanib (SU5416) is a small molecule receptor tyrosine kinase inhibitor that primarily targets the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), thereby inhibiting tumor angiogenesis. Interferon alfa-2b is a recombinant cytokine that exerts direct antiproliferative effects on tumor cells and modulates the host immune response. The combination was evaluated in a Phase II clinical trial sponsored by the City of Hope Medical Center and the California Cancer Consortium to determine if dual inhibition of angiogenesis and immune modulation could improve outcomes in patients with unresectable or metastatic renal cell carcinoma. Development of the semaxanib component was ultimately terminated following disappointing results in other Phase III trials.
- Brand names
- Intron A
- Other names
- interferon alfa-City of Hope Medical Center-renal cell carcinomaSU5416 + Interferon Alfa-2bSemaxanib + Interferon Alfa-2brecombinant interferon alfa-2b
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)IFNAR (Immune system modulation via type I interferon receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on semaxanib + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaxanib + interferon alfa-2b.